Referências
Principais artigos
Zucca E, Arcaini L, Buske C, et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Jan;31(1):17-29.Texto completo Resumo
Walewska R, Eyre TA, Barrington S, et al. Guideline for the diagnosis and management of marginal zone lymphomas: a British Society of Haematology guideline. Br J Haematol. 2024 Jan;204(1):86-107.Texto completo Resumo
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: B-cell lymphomas [internet publication].Texto completo
Artigos de referência
1. WHO Classification of Tumours Editorial Board. Haematolymphoid tumours: WHO classification of tumours. 5th ed. (vol. 11). Lyon (France): International Agency for Research on Cancer; 2022.
2. Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022 Sep 15;140(11):1229-53.Texto completo Resumo
3. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022 Jul;36(7):1720-48.Texto completo Resumo
4. Zucca E, Arcaini L, Buske C, et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Jan;31(1):17-29.Texto completo Resumo
5. Jaffe ES, Harris NL, Stein H, et al, eds. World Health Organization classification of tumors. Pathology and genetics: tumors of haemopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008.
6. Kiesewetter B, Lamm W, Dolak W, et al. Transformed mucosa-associated lymphoid tissue lymphomas: a single institution retrospective study including polymerase chain reaction-based clonality analysis. Br J Haematol. 2019 Aug;186(3):448-59.Texto completo Resumo
7. Kuo SH, Yeh KH, Lin CW, et al. Current status of the spectrum and therapeutics of Helicobacter pylori-negative mucosa-associated lymphoid tissue lymphoma. Cancers (Basel). 2022 Feb 16;14(4):1005.Texto completo Resumo
8. Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003 Apr 1;101(7):2489-95.Texto completo Resumo
9. Cohen SM, Petryk M, Varma M, et al. Non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue. Oncologist. 2006;11:1100-17. Resumo
10. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997;89:3909-3918.Texto completo Resumo
11. Zucca E, Bertoni F. The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. Blood. 2016 Apr 28;127(17):2082-92.Texto completo Resumo
12. Olszewski AJ, Castillo JJ. Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database. Cancer. 2013 Feb 1;119(3):629-38.Texto completo Resumo
13. Raderer M, Kiesewetter B, Ferreri AJ. Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). CA Cancer J Clin. 2016 Mar-Apr;66(2):153-71.Texto completo Resumo
14. Walewska R, Eyre TA, Barrington S, et al. Guideline for the diagnosis and management of marginal zone lymphomas: a British Society of Haematology guideline. Br J Haematol. 2024 Jan;204(1):86-107.Texto completo Resumo
15. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, et al. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet. 1991 Nov 9;338(8776):1175-6. Resumo
16. Sena Teixeira Mendes L, D Attygalle A, C Wotherspoon A. Helicobacter pylori infection in gastric extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma: a re-evaluation. Gut. 2014 Sep;63(9):1526-7. Resumo
17. Yamashita Y, Joshita S, Kobayashi H, et al. Primary hepatic extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in a patient with chronic hepatitis B virus infection: case report and summary of the literature. Medicina (Kaunas). 2021 Mar 18;57(3):280.Texto completo Resumo
18. Sagaert X, De Wolf-Peeters C, Noels H, et al. The pathogenesis of MALT lymphomas: where do we stand? Leukemia. 2007 Mar;21(3):389-96. Resumo
19. Wotherspoon AC. Extragastric MALT lymphoma. Gut. 2002 Aug;51(2):148-9.Texto completo Resumo
20. Schreuder MI, van den Brand M, Hebeda KM, et al. Novel developments in the pathogenesis and diagnosis of extranodal marginal zone lymphoma. J Hematop. 2017 Dec;10(3-4):91-107.Texto completo Resumo
21. Bacon CM, Du MQ, Dogan A. Mucosa-associated lymphoid tissue (MALT) lymphoma: a practical guide for pathologists. J Clin Pathol. 2007 Apr;60(4):361-72.Texto completo Resumo
22. de Jong D, Boot H, van Heerde P, et al. Histological grading in gastric lymphoma: pretreatment criteria and clinical relevance. Gastroenterology. 1997;112:1466-1474. Resumo
23. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: B-cell lymphomas [internet publication].Texto completo
24. Rodríguez-Sevilla JJ, Salar A. Recent Advances in the Genetic of MALT Lymphomas. Cancers (Basel). 2021 Dec 30;14(1):176.Texto completo Resumo
25. Kahl B, Yang D. Marginal zone lymphomas: management of nodal, splenic, and MALT NHL. Haematology Am Soc Hematol Educ Program. 2008:359-64.Texto completo Resumo
26. Liu H, Ye H, Ruskone-Fourmestraux A, et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology. 2002;122:1286-1294. Resumo
27. Ye H, Liu H, Raderer M, et al. High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. Blood. 2003;101:2547-2550.Texto completo Resumo
28. Liu H, Ye H, Dogan A, et al. T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. Blood. 2001;98:1182-1187. Resumo
29. Starostik P, Patzner J, Greiner A, et al. Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct pathogenetic pathways. Blood. 2002;99:3-9.Texto completo Resumo
30. Olszewska-Szopa M, Wróbel T. Gastrointestinal non-Hodgkin lymphomas. Adv Clin Exp Med. 2019 Aug;28(8):1119-24.Texto completo Resumo
31. Molina TJ, Lin P, Swerdlow SH, et al. Marginal zone lymphomas with plasmacytic differentiation and related disorders. Am J Clin Pathol. 2011 Aug;136(2):211-25.Texto completo Resumo
32. Cavalli F, Isaacson PG, Gascoyne RD, et al. MALT lymphomas. Haematology Am Soc Hematol Educ Program. 2001;241-258.Texto completo Resumo
33. Nakamura S, Yao T, Aoyagi K, et al. Helicobacter pylori and primary gastric lymphoma: a histopathologic and immunohistochemical analysis of 237 patients. Cancer. 1997 Jan 1;79(1):3-11.Texto completo Resumo
34. Laurent C, Cook JR, Yoshino T, et al. Follicular lymphoma and marginal zone lymphoma: how many diseases? Virchows Arch. 2023 Jan;482(1):149-62.Texto completo Resumo
35. Zucca E, Rossi D, Bertoni F. Marginal zone lymphomas. Hematol Oncol. 2023 Jun;41 Suppl 1:88-91.Texto completo Resumo
36. Almuhaideb A, Papathanasiou N, Bomanji J. 18F-FDG PET/CT imaging in oncology. Ann Saudi Med. 2011 Jan-Feb;31(1):3-13.Texto completo Resumo
37. Carrillo-Cruz E, Marín-Oyaga VA, de la Cruz Vicente F, et al. Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma. Hematol Oncol. 2015 Dec;33(4):151-8.Texto completo Resumo
38. Albano D, Giubbini R, Bertagna F. 18F-FDG PET/CT and primary hepatic MALT: a case series. Abdom Radiol (NY). 2016 Oct;41(10):1956-9.Texto completo Resumo
39. Nakamura S, Aoyagi K, Furuse M, et al. B-cell monoclonality precedes the development of gastric MALT lymphoma in Helicobacter pylori-associated chronic gastritis. Am J Pathol. 1998;152:1271-1279.Texto completo Resumo
40. Zucca E, Bertoni F, Roggero E, et al. Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. N Engl J Med. 1998;338:804-810.Texto completo Resumo
41. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med. 2012 Aug 30;367(9):826-33.Texto completo Resumo
42. Rohatiner A, d'Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 1994;5:397-400. Resumo
43. Blackledge G, Bush H, Dodge OG, et al. A study of gastro-intestinal lymphoma. Clin Oncol. 1979 Sep;5(3):209-19. Resumo
44. Ruskoné-Fourmestraux A, Dragosics B, Morgner A, et al. Paris staging system for primary gastrointestinal lymphomas. Gut. 2003 Jun;52(6):912-3.Texto completo Resumo
45. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Sep 20;32(27):3059-68.Texto completo Resumo
46. Schmelz R, Miehlke S, Thiede C, et al. Sequential H. pylori eradication and radiation therapy with reduced dose compared to standard dose for gastric MALT lymphoma stages IE & II1E: a prospective randomized trial. J Gastroenterol. 2019 May;54(5):388-395.Texto completo Resumo
47. Ruskoné-Fourmestraux A, Fischbach W, Aleman BM, et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut. 2011 Jun;60(6):747-58.Texto completo Resumo
48. Zullo A, Hassan C, Andriani A, et al. Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis. Am J Gastroenterol. 2009;104:1932-37. Resumo
49. Lemos FFB, de Castro CT, Calmon MS, et al. Effectiveness of Helicobacter pylori eradication in the treatment of early-stage gastric mucosa-associated lymphoid tissue lymphoma: an up-to-date meta-analysis. World J Gastroenterol. 2023 Apr 14;29(14):2202-21.Texto completo Resumo
50. Zullo A, Hassan C, Andriani A, et al. Treatment of low-grade gastric MALT-lymphoma unresponsive to Helicobacter pylori therapy: a pooled-data analysis. Med Oncol. 2010;27:291-295. Resumo
51. Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005 Mar 20;23(9):1979-83.Texto completo Resumo
52. Amiot A, Lévy M, Copie-Bergman C, et al. Rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomised observational study. Aliment Pharmacol Ther. 2014 Mar;39(6):619-28.Texto completo Resumo
53. Raderer M, Kiesewetter B. How I treat MALT lymphoma: 'a subjective interpretation of the gospel according to Isaacson….'. ESMO Open. 2020 Jul;5(4):e000812.Texto completo Resumo
54. Liu Y, Gao Y, Jin L, et al. Safety and efficacy of intralesional rituximab injection versus involved site radiation therapy in primary ocular adnexal MALT lymphoma: study protocol for a multicentre randomised controlled trial. BMJ Open. 2024 Nov 27;14(11):e084904.Texto completo Resumo
55. Ferreri AJ, Govi S, Pasini E, et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol. 2012 Aug 20;30(24):2988-94.Texto completo Resumo
56. Zinzani PL, Martelli M, Poletti V, et al. Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2008 Sep;93(9):1364-71.Texto completo Resumo
57. Borie R, Wislez M, Antoine M, et al. Pulmonary mucosa-associated lymphoid tissue lymphoma revisited. Eur Respir J. 2016 Apr;47(4):1244-60.Texto completo Resumo
58. Okamura I, Imai H, Mori K, et al. Rituximab monotherapy as a first-line treatment for pulmonary mucosa-associated lymphoid tissue lymphoma. Int J Hematol. 2015 Jan;101(1):46-51. Resumo
59. Freret ME, Tringale KR, Boe L, et al. Very low-dose radiotherapy for extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue. Leuk Lymphoma. 2023 Dec;64(13):2195-201.Texto completo Resumo
60. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: primary cutaneous lymphomas. [internet publication]Texto completo
61. Specht L, Dabaja B, Illidge T, et al. Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):32-9.Texto completo Resumo
62. Roggero E, Zucca E, Mainetti C, et al. Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Hum Pathol. 2000 Feb;31(2):263-8. Resumo
63. Lolli G, Argnani L, Broccoli A, et al. (90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - the Zeno Study. Br J Haematol. 2020 Apr;189(1):e6-9.Texto completo Resumo
64. Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022 Jan;23(1):91-103. Resumo
65. Strati P, Coleman M, Champion R, et al. A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. Br J Haematol. 2022 Oct;199(1):76-85.Texto completo Resumo
66. Patel K, Vose JM, Nasta ND, et al. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed/refractory marginal zone lymphoma: results from phase 1/2 BRUIN study. Blood. 2023;142(suppl 1):1660.Texto completo
67. Cheah CY, Zucca E, Rossi D, et al. Marginal zone lymphoma: present status and future perspectives. Haematologica. 2022 Jan 1;107(1):35-43.Texto completo Resumo
68. Thieblemont C, Cascione L, Conconi A, et al. A MALT lymphoma prognostic index. Blood. 2017 Sep 21;130(12):1409-17.Texto completo Resumo
69. Alderuccio JP, Reis IM, Habermann TM, et al. Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma. Am J Hematol. 2022 Dec;97(12):1529-1537.Texto completo Resumo
70. Wündisch T, Thiede C, Morgner A, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol. 2005 Nov 1;23(31):8018-24. Resumo
71. Fischbach W, Goebeler-Kolve ME, Dragosics B, et al. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut. 2004 Jan;53(1):34-7.Texto completo Resumo
72. Zullo A, Hassan C, Cristofari F,et al. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol. 2010;8:105-110. Resumo
73. Zucca E, Cavalli F. Are antibiotics the treatment of choice for gastric lymphoma? Curr Hematol Rep. 2004;3:11-16. Resumo
74. Yahalom J, Xu AJ, Noy A, et al. Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patients. Blood Adv. 2021 Apr 13;5(7):1830-6.Texto completo Resumo
75. Kang HJ, Kim WS, Kim SJ, et al. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol. 2012 Apr;91(4):543-51. Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal